Difference between revisions of "Iobenguane I 131 (Azedra)"
Jump to navigation
Jump to search
m |
m |
||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2018-07-30: Initial approval for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic [[pheochromocytoma]] or [[paraganglioma]] who require systemic anticancer therapy. ''(Based on MIP-IB12B)'' | *2018-07-30: Initial approval for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic [[pheochromocytoma]] or [[paraganglioma]] who require systemic anticancer therapy. ''(Based on MIP-IB12B)'' | ||
| − | + | ==History of changes in PMDA indication== | |
| + | *2021-09-27: Newly indicated for the treatment of unresectable MIBG-positive [[pheochromocytoma]]/[[paraganglioma]]. | ||
==Also known as== | ==Also known as== | ||
*'''Generic names:''' <sup>131</sup>I-Metaiodobenzylguanidine, <sup>131</sup>I-MIBG, [131I]MIBG, m-[131I]iodobenzylguanidine | *'''Generic names:''' <sup>131</sup>I-Metaiodobenzylguanidine, <sup>131</sup>I-MIBG, [131I]MIBG, m-[131I]iodobenzylguanidine | ||
| − | *'''Brand name:''' Azedra | + | *'''Brand name:''' Azedra, PheoMIBG-I 131, Raiatt MIBG-I 131 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 17: | Line 18: | ||
[[Category:Pheochromocytoma medications]] | [[Category:Pheochromocytoma medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
| + | [[Category:PMDA approved in 2021]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 19:19, 6 June 2023
General information
Radioactive MIBG
Diseases for which it was used
History of changes in FDA indication
- 2018-07-30: Initial approval for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. (Based on MIP-IB12B)
History of changes in PMDA indication
- 2021-09-27: Newly indicated for the treatment of unresectable MIBG-positive pheochromocytoma/paraganglioma.
Also known as
- Generic names: 131I-Metaiodobenzylguanidine, 131I-MIBG, [131I]MIBG, m-[131I]iodobenzylguanidine
- Brand name: Azedra, PheoMIBG-I 131, Raiatt MIBG-I 131